Inclusion Criteria:  Men or women ≥18 years old Pathologically diagnosed, previously treated, advanced tumor with KRAS p.G12C mutation Adequate organ function Measurable disease per RECIST 1.1 criteria.  Exclusion Criteria:  Significant concomitant diseases Active brain metastases Previous treatment with KRAS G12C inhibitor.